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The wound healing process concludes with down-
regulation of ®broblast activity. Clinical observations
suggest that the regenerating epidermis suppresses
this activity. An important regulator of ®broblast
activity is the ®brogenic cytokine connective tissue
growth factor. We hypothesized that epidermal
keratinocytes may affect ®broblast activity via this
cytokine. We demonstrate keratinocyte-mediated
suppression of connective tissue growth factor at
both the mRNA and protein levels by around 50%
or more when ®broblasts were cultured in multiwell
plates with keratinocyte cultures in accompanying
semipermeable cell culture inserts, or stimulated by
keratinocyte-conditioned media. Both basal and
transforming-growth-factor-b1-stimulated levels of
connective tissue growth factor were inhibited. A 3 h
coculture period with keratinocytes was suf®cient to
suppress connective tissue growth factor expression
by ®broblasts, but the inhibition developed over a
time period of around 16 h. The putative keratino-
cyte-derived factor(s) responsible for these effects
was found to be soluble and stable. By analyzing
cytokines secreted by keratinocytes we identi®ed
interleukin-1a as a potent inhibitor of connective tis-
sue growth factor mRNA expression in ®broblasts.
Involvement of this cytokine in keratinocyte-medi-
ated connective tissue growth factor suppression was
con®rmed by using anti-interleukin-1a antibodies.
Tumor necrosis factor a or prostaglandins did not
appear to be involved. In conclusion, our results
indicate that interleukin-1a secretion by keratino-
cytes provides a mechanism for the downregulation
of connective tissue activity during the end-stage of
wound healing, when epithelia coverage has
developed over the wound area. Key words: coculture/
re-epithelialization/transforming growth factor b1/wound
healing. J Invest Dermatol 119:449±455, 2002
W
ound healing is dependent on the recruitment
of several cell types that appear in the wound
area in a temporally and spatially de®ned
manner. Re-epithelialization largely coincides
with the recruitment of dermal ®broblasts and it
is likely that crosstalk between epidermal keratinocytes and
®broblasts is important during the rebuilding of tissue integrity
(Fusenig et al, 1994). Healing of extensive wounds often results in
excessive scarring, dis®guring, and functional impairment of the
affected area (Haverstock, 2001). This is a particular problem in the
healing of large burn wounds, and it appears that an early re-
epithelialization or coverage of the wounded area with autologous
skin grafts limits excessive deposition of connective tissue.
Experiments in which keratinocytes were cocultured with
®broblasts have demonstrated establishment of paracrine loops of
cytokines between the two cell types (Maas-Szabowski et al, 2000;
Szabowski et al, 2000), a phenomenon that most probably also
operates in vivo to regulate cellular function (Goretsky et al, 1996).
Epidermal keratinocytes has been demonstrated downregulate the
production of the major matrix component of the dermis, collagen
I, by ®broblasts (Lacroix et al, 1995; Garner, 1998). Several
®brogenic cytokines have been described. Transforming growth
factor b1 (TGF-b1) is a potent stimulator of various extracellular
matrix molecules, as well as of inhibitors of matrix degrading
enzymes (Roberts et al, 1990). Connective tissue growth factor
(CTGF) is another regulatory protein acting downstream of TGF-
b1, and promoting proliferation and collagen synthesis of
mesenchymal cells. It has been hypothesized that CTGF is a
TGF-b-stimulated regulator speci®c for the mesenchymal com-
partment (Grotendorst, 1997). TGF-b1 stimulates expression of
CTGF, but not all effects ascribed to TGF-b1 are mediated by
CTGF (Grotendorst, 1997). Conversely, CTGF may act indepen-
dently of TGF-b signaling or expression (Dammeier et al, 1998;
Chambers et al, 2000; Holmes et al, 2001). Both TGF-b1 and
CTGF are upregulated during wound healing (Igarashi et al, 1993;
Frank et al, 1996) and overexpressed in various ®brotic conditions
(Border and Noble, 1994; Lasky et al, 1998; Blobe et al, 2000; Shi-
wen et al, 2000; Williams et al, 2000).
In this work, using in vitro models, we tested the hypothesis that
epidermal keratinocytes act to suppress expression of the ®brogenic
cytokine CTGF in ®broblasts.
MATERIALS AND METHODS
Antibodies and cytokines Polyclonal antihuman CTGF antibodies
and recombinant CTGF ligands were obtained from Fibrogen (San
Francisco, CA). Polyclonal anti-b-tubulin antibodies came from Santa
Cruz Biotechnology (Santa Cruz, CA). Neutralizing interleukin-1a (IL-
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1a) antibodies were obtained from R&D Systems (Minneapolis, MN).
Recombinant IL-1a and TGF-b1 were obtained from Sigma (St. Louis,
MO).
Cells Cells were isolated from samples of skin from young individuals
undergoing plastic surgery at our department. Epidermal keratinocytes
were isolated from human skin as described previously (Rheinwald,
1980). Brie¯y, skin samples were treated with dispase and epidermis was
mechanically separated from the underlying dermis; this was followed by
mechanical fragmentation and treatment of the separated epidermal sheets
with trypsin. Keratinocytes were propagated on irradiated 3T3 feeder
cells in Dulbecco's modi®ed Eagle's medium (DMEM)/Ham's F12 (4:1)
supplemented with 5 mg per ml Zn-free insulin (donated by Lilly
Research Laboratories), 2 nM 3,3¢,5-triiodo-D-thyronine (Sigma), 0.4 mg
per ml hydrocortisone (Sigma), 0.1 nM choleratoxin (Sigma), 10 ng per
ml epidermal growth factor (Austral Biologicals, San Ramon, CA),
24 mg per ml adenine, 10% fetal bovine serum (HyClone, Logan, UT),
and 50 mg per ml gentamicin. Fibroblasts were isolated from the dermal
compartment by collagenase treatment and subcultured in DMEM
supplemented with 10% bovine calf serum (HyClone) and 50 mg per ml
gentamicin. Subcon¯uent cells were washed with phosphate-buffered
saline and detached by treatment with trypsin. Cells at population
doubling level 5±10 were used for the experiments.
Coculture 0.3 3 106 ®broblasts were cultured in plastic dishes [six-
well Falcon multiwell plates, surface area 9.62 cm2 (BD Labware,
Franklin Lakes, NJ)], and 0.3 3 106 keratinocytes were seeded in Falcon
polyurethane cell culture inserts (0.4 mm pore diameter). The inserts
were precoated with a mixture of 10 mg per ml bovine plasma
®bronectin (Gibco BRL/Life Technology, Paisley, U.K.), 30 mg per ml
bovine collagen (Vitrogen, Cohesion, Palo Alto, CA), and 10 mg per ml
bovine serum albumin (Sigma) for 2 h at 37°C. As controls, 0.2 3 106
®broblasts were grown in inserts instead of keratinocytes. Cell cultures
were prepared in separate compartments (wells and inserts) 1 d before
start of the cocultures. The culture medium during this period was the
standard growth medium for the two cell types as described above.
Upon initiation of the cocultures, the medium was changed to DMEM/
Ham's F12 (4:1) supplemented with 0.5% fetal bovine serum (HyClone),
and the inserts were combined with the wells. The total volume was
4 ml (2 + 2 ml). At this point cell densities were nearly con¯uent in
both compartments. Coculture time was continued for various lengths of
time as indicated. TGF-b1 was added to both compartments at the start
of the cocultures in some experiments.
Keratinocyte-conditioned medium Two 3 106 keratinocytes were
seeded in 75 cm2 ¯asks precoated with collagen/®bronectin/bovine
serum albumin as described above. The next day cells were washed with
phosphate-buffered saline and conditioned with 10 ml DMEM/Ham's
F12 (4:1) supplemented with 0.5% fetal bovine serum for 3 h. Cell
density was approximately 50% at this point. Two milliliters of the
conditioned medium was added to ®broblast cultures in six-well plates
and the cultures were continued for various lengths of time, as indicated,
before analysis of CTGF mRNA or protein levels. Conditioned medium
from ®broblasts was run in parallel and used as a control for
keratinocyte-conditioned medium. TGF-b1 was added to the
conditioned medium before the latter was added to the ®broblasts.
Northern blotting RNA was extracted from cells using TRIzol
reagent (Life Technology). Total RNA was quantitated ¯uorometrically
(SYBR Green II, FMC Bioproducts, Rockland, ME). The RNA was
denaturated in formaldehyde, separated by agarose gel electrophoresis,
and transferred to nylon membranes (Hybond N+, Amersham Pharmacia
Biotech, Buckinghamshire, U.K.). Fixation of the RNA was performed
by UV-crosslinking (GS GeneLinker, Bio-Rad, Hercules, CA), and the
membranes were prehybridized for 15 min at 65°C in Rapid Hyb Buffer
(Amersham Pharmacia Biotech). cDNA for CTGF was from Fibrogen.
As control probe for RNA loading, oligonucleotides coding for 18S or
28S ribosomal RNA (Barbu and Dautry, 1989; Carlson et al, 1993) were
used. cDNAs were labeled with [a-32P]dCTP using the Megaprime kit
(Amersham Pharmacia Biotech) and the control oligonucleotides were
labeled with [g-32P]ATP and polynucleotide kinase (Barbu and Dautry,
1989). cDNA probes were denatured and added to prehybridization
buffer, and hybridization proceeded for 2 h at 65°C. Oligonucleotide
probes were prehybridized and hybridized at 37°C. For cDNA probes,
membranes were washed twice in 2 3 sodium citrate/chloride buffer
(SSC)/0.1% sodium dodecyl sulfate (SDS) at room temperature and then
in 0.2 3 SSC/0.1% SDS at 65°C. For oligonucleotide probes,
membranes were washed in 2 3 SSC/0.1% SDS at room temperature
followed by 0.2 3 SSC/0.1% SDS at 37°C. Signals were detected and
quanti®ed by autoradiography and densitometry (SigmaGel Software,
Jandel Scienti®c, Chicago, IL). Reprobing with 28S or 18S probes was
performed after removal of RNA from the membranes by boiling in
0.1% SDS. The size of the CTGF transcript was estimated at 2.4 kb as
reported previously (Bradham et al, 1991).
Western blotting The culture medium was removed and the cells
were washed with phosphate-buffered saline. Cells were solubilized in
RIPA buffer (0.15 M NaCl, 0.05 M Tris±HCl, 0.1% SDS, 1% Igepal
CA-630 (Sigma), 5 mg per ml Na deoxycholate) containing protease
inhibitors. Protein concentration was determined using the Bio-Rad DC
protein assay (Bio-Rad, Hercules, CA). Equal amounts of proteins
(40 mg) were boiled in SDS sample buffer and separated by SDS
polyacrylamide gel electrophoresis under nonreducing conditions.
Proteins were electro-transferred to Hybond-C nitrocellulose membranes
(Amersham Pharmacia Biotech). Immunoblotted proteins were incubated
with rabbit polyclonal anti-CTGF antibodies and anti-b-tubulin
antibodies followed by incubation with horseradish-peroxidase-
conjugated secondary antibodies and chemiluminescence detection (ECL,
Amersham Pharmacia Biotech). Recombinant CTGF was used as control.
CTGF protein was detected as a doublet with a relative molecular weight
of around 38 kDa (con®rmed by personal communication with Dr.
Patricia Segarini, Fibrogen, CA). b-Tubulin migrated with a relative
molecular weight of around 52 kDa.
Determination of cytokine levels Analysis of the concentration of
cytokines in keratinocyte-conditioned media was performed with
commercial enzyme-linked immunosorbent assay (ELISA) kits for IL-1a,
IL-1b, tumor necrosis factor a (TNF-a), and interferon-g (IFN-g)
(Biotrak, Amersham Pharmacia Biotech).
Statistical analysis All results are presented as means 6 SEM unless
otherwise stated. Student's t tests (unpaired) were used for statistical
analysis. n values signify the number of independent experiments
performed. p-values less than 0.05 were considered statistically
signi®cant.
RESULTS
Keratinocytes inhibit expression of CTGF in ®broblasts in
the absence of physical contacts Human keratinocytes and
dermal ®broblasts were cultured physically separated in cocultures,
as described in Materials and Methods. CTGF mRNA and protein
expression in ®broblasts were investigated by Northern blotting and
Western blotting, respectively. mRNA levels were determined
after 16 and 48 h of coculture, and protein levels were measured
after 48 h of coculture. After 16 h the level of CTGF mRNA in
®broblasts from cocultures was 49% 6 7.8% of the level in
®broblasts from control cultures (n = 3, p = 0.0006), and after
48 h CTGF mRNA levels were 64% 6 5.0% in ®broblasts from
cocultures compared to control cultures (n = 8, p < 0.0001)
(Fig 1A). The same pattern was observed when cellular CTGF
protein was measured: CTGF protein was 69% 6 5.8% in
cocultures compared to control cultures after 48 h (n = 5, p =
0.0008) (Fig 1C). Next, we investigated whether keratinocytes
could also inhibit TGF-b1-stimulated CTGF expression. In the
presence of 40 pM TGF-b1, CTGF mRNA and protein levels
were increased in ®broblast monocultures, as expected (Fig 1B, C).
Keratinocytes were still able to suppress ®broblast CTGF expression
to the same extent as in the absence of TGF-b1, however; when
TGF-b1 was added, the level of CTGF mRNA in ®broblasts was
41% 6 9.3% in cocultures compared to control cultures after 16 h
(n = 3, p = 0.0032) (Fig 1B), and after 48 h CTGF protein levels
were 52% 6 1.4% in cocultures compared to control cultures
(n = 2) (Fig 1C). In summary, via soluble factors keratinocytes
were able to inhibit basal or TGF-b1-stimulated CTGF mRNA
and protein in ®broblasts.
A short coculture time with keratinocytes, or conditioned
medium from keratinocytes, is suf®cient for suppression of
CTGF in ®broblasts In order to investigate more closely the
ef®ciency of keratinocyte-mediated CTGF suppression, ®broblasts
were exposed to keratinocytes for short time periods. Fibroblasts
were cocultured with keratinocytes in inserts for 3 or 6 h, inserts
were then removed, and CTGF mRNA was analyzed 24 h after
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initial exposure to keratinocytes. Twenty picomoles TGF-b1 was
added immediately after removal of the inserts. A 3 h keratinocyte
interaction resulted in a drop in the CTGF mRNA level in
®broblasts to 38% 6 6.2% of control levels (n = 6, p < 0.0001),
and after a 6 h coculture time the level was 46% 6 6.8% compared
to control levels (n = 2) (Fig 2A). The inhibition of the CTGF
mRNA level was followed by a corresponding decrease in cellular
CTGF protein; a 3 h keratinocyte interaction resulted in a decrease
to 30% 6 11% relative to control levels 24 h after initial exposure
to keratinocytes (n = 2) (Fig 2B). To investigate if suppression of
CTGF depended on a paracrine loop between the two cell types,
i.e., if the presence of ®broblasts was necessary in order for
keratinocyte-derived CTGF inhibitory factor(s) to be produced,
®broblasts were subjected to conditioned medium from keratino-
cytes. Medium that had been incubated with keratinocytes or
®broblasts (control) for 3 h was added to ®broblasts. At this point
20 pM TGF-b1 was also added to the cultures. After 16 h the level
of CTGF mRNA in ®broblasts cultured in keratinocyte-
conditioned medium was 31% 6 13% compared to control levels
(n = 3, p = 0.0062) (Fig 3A). Similarly, CTGF protein expression
decreased to 29% 6 20% (n = 2) in ®broblasts cultured in
keratinocyte-conditioned medium compared to control levels
(Fig 3B). Thus, the presence of ®broblasts was not necessary for
production of CTGF inhibitory factor(s) by keratinocytes.
Inhibition of keratinocyte-mediated CTGF suppression is
developed over time, and sustained in ®broblasts In order
to study the dynamics of the keratinocyte-mediated suppression of
CTGF, we investigated CTGF mRNA and protein expression 6
and 20 h after a coculture period of 3 h. Twenty picomoles TGF-
b1 was added to the cultures after removal of inserts. At 6 h the
level of CTGF mRNA was not changed signi®cantly, whereas at
20 h there was a strong suppression of CTGF mRNA in ®broblasts
cocultured with keratinocytes (Fig 4A). CTGF protein levels
followed a similar pattern; at 6 h the level of cellular CTGF protein
was unchanged compared to control levels, but at 20 h CTGF was
strongly downregulated (Fig 4B). To further investigate the
temporal pattern of CTGF downregulation, we cultured
®broblasts in keratinocyte-conditioned medium and analyzed
mRNA levels at different time points. Twelve hours after
addition of keratinocyte-conditioned medium there was still little
change in CTGF mRNA expression, whereas after 24 or 48 h
there was a strong relative downregulation of CTGF mRNA in
®broblasts (Fig 5). To further con®rm that the keratinocyte-
derived suppression of CTGF is sustained in ®broblasts, the
®broblasts were exposed to keratinocyte-conditioned medium for
16 or 40 h before addition of 20 pM TGF-b1. CTGF mRNA was
analyzed at different time periods after addition of TGF-b1.
Although the response to TGF-b1 diminished with time, relative
suppression of CTGF mRNA was strong at all time points in
®broblasts exposed to keratinocyte-conditioned medium. If TGF-
b1 was added late, i.e., after 40 h of culture, suppression of CTGF
mRNA by keratinocyte-conditioned medium was still of the same
Figure 2. A 3 h coculture with keratinocytes is suf®cient for
suppression of CTGF mRNA and protein expression in
®broblasts. Fibroblasts were cultured for 3 or 6 h with keratinocytes in
cell culture inserts. Inserts were removed, 20 pM TGF-b1 was added,
and ®broblasts were cultured for a total of 24 h following initial
exposure to keratinocytes. CTGF mRNA was analyzed by Northern
blotting and cellular CTGF protein by Western blotting. (A) CTGF
mRNA expression in ®broblasts exposed to keratinocytes for 3 h (n = 6)
or 6 h (n = 2). (B) CTGF protein expression in ®broblasts exposed to
keratinocytes for 3 h (n = 2). A 3 h coculture with ®broblasts in inserts
was used as the control. Values are expressed as means 6 SEM, n =
number of separate experiments performed. (*Signi®cant at p < 0.01.) F,
®broblasts in inserts (control); K, keratinocytes in inserts.
Figure 1. Keratinocytes downregulate CTGF expression in
®broblasts in the absence of physical contacts. Fibroblasts were
cocultured with keratinocytes or ®broblasts (control) in cell culture
inserts in the absence or presence of 40 pM TGF-b1. After 16 or 48 h
®broblasts were subjected to Northern blotting for analysis of CTGF
mRNA expression. In parallel cultures, cellular CTGF protein level was
determined by Western blotting. Levels of 28S ribosomal RNA and
b-tubulin were used as internal controls. (A) CTGF mRNA expression
after 16 h (n = 3) and 48 h (n = 8) of coculture in the absence of TGF-
b1. (B) CTGF mRNA expression after 16 h in the presence of TGF-b1
(n = 3). (C) CTGF protein level after 48 h of coculture in the absence
(n = 5) or presence (n = 2) of TGF-b1. Values are expressed as means 6
SEM, n = number of separate experiments performed. (*Signi®cant at
p < 0.01.) F, ®broblasts in inserts (control); K, keratinocytes in inserts;
Recomb, recombinant CTGF protein.
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magnitude (Fig 6). Taken together, the results show that
stimulation of ®broblasts with keratinocyte-derived factors
induces a suppression of CTGF expression that is developed over
time and fully established after around 16±24 h. The ®broblasts so
induced to inhibit CTGF expression sustain this phenotype for at
least 24 h.
The putative keratinocyte-derived factor(s) suppressing
CTGF expression is stable and insensitive to treatment
with indomethacin In an effort to characterize the keratino-
cyte-derived factor(s) responsible for suppression of CTGF, we
determined its resistance to inactivation after incubation at 37°C for
24 h. Fibroblasts were cultured in keratinocyte-conditioned
medium that had been incubated at 37°C for 0 or 24 h. After
16 h in these media, 20 pM TGF-b1 was added and CTGF
mRNA levels were analyzed after an additional 3 h. The
magnitude of suppression was similar in media that had been
incubated for 0 or 24 h at 37°C, and conditioned media that had
been stored at ±70°C for 4 wk also showed a similar potency in
suppressing CTGF expression (Fig 7A). Previous work has
demonstrated the ability of prostaglandins to downregulate the
expression of CTGF in ®broblasts (Ricupero et al, 1999; Stratton et
al, 2001). We therefore investigated if the keratinocyte-mediated
CTGF suppression could be reversed by the addition of
indomethacin, a potent inhibitor of prostaglandin synthesis.
Fibroblasts were cultured for 16 h in keratinocyte-conditioned
medium containing 10 mM indomethacin. Twenty picomoles
TGF-b1 was added and CTGF mRNA was measured after
another 3 h. There was no difference in the suppression of CTGF
with or without the addition of indomethacin (Fig 7B). This
®nding is supported by the observation that the putative
keratinocyte-derived factor(s) is stable, as prostaglandins typically
have a very short half-life.
Figure 4. Keratinocyte-mediated CTGF suppression is developed
over time in ®broblasts. Fibroblasts were cocultured for 3 h with
keratinocytes or ®broblasts (control) in inserts. Inserts were removed,
20 pM TGF-b1 was added, and CTGF mRNA and protein were
analyzed by (A) Northern and (B) Western blotting after an additional 6
and 20 h of culture. The experiments were repeated with qualitatively
identical results. F, ®broblasts in inserts (control); K, keratinocytes in
inserts.
Figure 5. CTGF suppression is developed over time in ®broblasts
in the presence of keratinocyte-conditioned medium. Fibroblasts
were subjected to conditioned medium from keratinocytes or ®broblasts
(control). Twenty picomoles TGF-b1 was added and CTGF mRNA
levels were analyzed by northern blotting after different time periods.
The experiments were repeated with qualitatively identical results.
FCM, ®broblast-conditioned medium (control); KCM, keratinocyte-
conditioned medium.
Figure 3. Conditioned medium from keratinocytes can replace
inserts with keratinocytes for suppression of CTGF mRNA and
protein in ®broblasts. Fibroblasts were subjected to conditioned
medium from keratinocytes or ®broblasts (control) containing 20 pM
TGF-b1, and CTGF expression was analyzed after 16 h. (A) CTGF
mRNA expression as determined by Northern blotting (n = 3). (B)
Cellular CTGF protein level as determined by Western blotting (n = 2).
Values are expressed as means 6 SEM, n = number of separate
experiments performed. (*Signi®cant at p < 0.01.) FCM, ®broblast-
conditioned medium (control); KCM, keratinocyte-conditioned
medium.
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Identi®cation of IL-1a as a major keratinocyte-derived
mediator of CTGF suppression in ®broblasts In order to try
to identify a keratinocyte-mediated factor responsible for inhibition
of CTGF expression in ®broblasts, we ®rst analyzed the level of
cytokines secreted by keratinocytes in our culture system. For this
purpose we selected IL-1a, IL-1b, TNF-a, and IFN-g, which have
been demonstrated to be produced by keratinocytes in various
conditions, and/or have been demonstrated to have effects on
®broblast activity (Jimenez et al, 1984; Burbach et al, 2001). As
measured by ELISA, only IL-1a was detected at a signi®cant level.
The amount produced by keratinocytes in a 3 h culture was
23.7 6 7.7 pg per ml (n = 5) (Fig 8A). This prompted us to test
the effect of ectopically added IL-1a on CTGF expression. IL-1a
was added to ®broblasts in various concentrations together with
20 pM TGF-b1, and CTGF mRNA was analyzed after 16 h. We
found that IL-1a was a potent inhibitor of TGF-b-stimulated
CTGF expression, with an IC50 of around 10 pg per ml in our
system (Fig 8B). To test if IL-1a was a true mediator of
suppression of CTGF in our system, we added neutralizing anti-
IL-1a antibodies to keratinocyte-conditioned medium before
treatment of ®broblasts. Interestingly, the majority of the effect of
conditioned medium was abrogated by the addition of 0.4 mg per
ml of the antibody (Fig 9). Addition of control IgG did not have an
effect (not shown). Thus, keratinocyte-derived IL-1a is a potent
suppressor of CTGF and is a major inhibitor of CTGF expression
in our models.
DISCUSSION
We demonstrate the ability of epidermal keratinocytes to suppress
the expression of CTGF in dermal ®broblasts by secretion of
soluble factors, and this occurs in the absence of physical contact
between the two cell types. A major mediator of this suppression
was identi®ed as IL-1a, whereas TNF-a and prostaglandins did not
appear to be involved. Suppression of CTGF mRNA and protein
was effective both in cocultures and when conditioned medium
from keratinocytes was used to stimulate the ®broblasts. The CTGF
suppressive ®broblast phenotype was developed over about 16 h
and it was sustained.
Paracrine loops between keratinocytes and ®broblasts have been
suggested to be important for basement membrane formation and
®broblast-supported keratinocyte proliferation (Maas-Szabowski
et al, 1999). These paracrine interactions were found to involve
IL-1 produced by keratinocytes, which stimulate expression of IL-1
type I receptors and keratinocyte growth factor in ®broblasts
(Maas-Szabowski et al, 1999, 2000). For the generation of the
CTGF suppressive ®broblast phenotype, however, we found that
such a mutual interaction was not necessary, as conditioned
medium from keratinocytes was at least as effective as the coculture
approach. TGF-b1 was added to stimulate CTGF expression as a
Figure 6. Keratinocyte-mediated CTGF suppression is sustained
in ®broblasts. Fibroblasts were incubated with conditioned medium
from keratinocytes or ®broblasts (control) for 16 or 40 h. Twenty
picomoles TGF-b1 was added and CTGF mRNA levels were analyzed
by Northern blotting after different time periods as indicated. The
experiment was repeated with qualitatively identical results. FCM,
®broblast-conditioned medium (control); KCM, keratinocyte-
conditioned medium.
Figure 7. The putative keratinocyte-derived factor(s) suppressing
CTGF expression is stable and insensitive to treatment with
indomethacin. (A) Keratinocyte-conditioned medium was incubated at
37°C for 0 or 24 h, and then added to ®broblasts for 16 h. Twenty
picomoles TGF-b1 was added and CTGF mRNA levels were analyzed
by northern blotting after an additional 3 h. Similarly, keratinocyte-
conditioned medium that had been stored at ±70°C for 4 wk was tested
to evaluate its potency in inhibiting TGF-b-stimulated CTGF mRNA
expression. Fibroblast-conditioned media that were treated identically
were used as controls. (B) Keratinocyte- or ®broblast-conditioned
medium containing 10 mM indomethacin was added to ®broblasts. After
16 h 20 pM TGF-b1 was added and CTGF mRNA levels were
analyzed by Northern blotting after an additional 3 h. The experiments
were repeated with identical results. Indo, indomethacin; FCM,
®broblast-conditioned medium (control); KCM, keratinocyte-
conditioned medium.
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standard procedure in our experiments, because the basal CTGF
expression is very low and TGF-b1 is normally present in
reparative processes when re-epithelialization is ongoing (Frank
et al, 1996). We identi®ed IL-1a as a major mediator of
keratinocyte-derived CTGF suppression on the basis of the
following results: (i) keratinocytes produce signi®cant amounts of
IL-1a; (ii) IL-1a inhibits basal and TGF-b1-stimulated CTGF
expression; (iii) neutralizing IL-1a antibodies reverse a major part
of keratinocyte-mediated suppression of CTGF expression; and (iv)
the putative keratinocyte-derived factor(s) is stable. In agreement
with earlier reports (Delaporte et al, 1989; Kratz et al, 1991) we
detected a slight increase (around 25%) in the number of ®broblasts
cocultured with keratinocytes (not shown), indicating that CTGF
suppression is not caused by a decreased viability of the ®broblasts.
In addition, overall protein synthesis does not change as a result of
coculture for 48 h in the presence of 0.5% fetal bovine serum (not
shown).
IL-1 stimulates production of prostaglandins (Albrightson et al,
1985; Dukovich et al, 1986), and prostaglandins have been shown
to inhibit CTGF expression in ®broblasts (Ricupero et al, 1999;
Stratton et al, 2001). In our hands, however, the IL-1a effect is
most probably not mediated via prostaglandins as indomethacin, a
potent inhibitor of prostaglandin synthesis, could not reverse
keratinocyte-mediated CTGF suppression. Importantly, our ®nd-
ings suggest that the amount of IL-1a in keratinocyte-conditioned
media can explain the full effect of keratinocyte-mediated CTGF
suppression. If other factors secreted by keratinocytes have an effect
on CTGF expression, this is probably minor in our experimental
model. We did not detect signi®cant amounts of IL-1b in
keratinocyte-conditioned media. Keratinocytes may produce sig-
ni®cant amounts of pro-IL-1b, however, which is converted to
active IL-1b in vivo and may affect CTGF expression during tissue
repair (Black et al, 1988; Hazuda et al, 1990). Indeed, IL-1b also
demonstrates CTGF suppressive activity (unpublished observation).
Being an immediate early gene product, CTGF mRNA expression
in ®broblasts is induced rapidly by, for example, TGF-b1
stimulation (Kucich et al, 2001, and unpublished observation).
The suppression of CTGF observed in our work developed over
time, however, and was sustained. This implies that a complex
machinery is initiated by keratinocyte-conditioned medium/IL-1a
to sustain an inhibitory phenotype. Further studies will be required
to elucidate the precise intracellular mechanism mediating the
effects of IL-1a on the expression of CTGF.
Our results are of relevance to wound healing, and it is possible
that keratinocytes downregulate CTGF expression in dermal
®broblasts during re-epithelialization in vivo. Future investigations
will show if the lack of viable keratinocytes, and the delayed re-
epithelialization seen in large burns, result in overexpression of
CTGF. Such an overexpression could be due to a de®ciency of IL-
1a, and could be, at least partly, responsible for the formation of
hypertrophic scars in these situations. Indeed, it was recently
demonstrated that hypertrophic scarring after surgery is accom-
panied by a decreased epidermal expression of IL-1a (Niessen et al,
2001). An interesting extension of this is the possibility that a
de®ciency in the response to keratinocyte-derived factors/IL-1a
could contribute to a continued activity of ®broblasts/production
of extracellular matrix, despite an early re-epithelialization, result-
ing in excessive scarring or keloid formation. In conclusion, our
results support the view that epidermal keratinocytes have a
suppressive effect on dermal ®broblast activity.
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Figure 8. IL-1a is secreted by keratinocytes and is suppressing
CTGF mRNA in ®broblasts. (A) Keratinocyte-conditioned medium,
prepared as described in Materials and Methods, was subjected to analysis
of the cytokines IL-1a, IL-1b, IFN-g, and TNF-a by ELISA. Values are
expressed as mean 6 SEM of duplicates of ®ve (IL-1a) or three (IL-1b,
IFN-g, and TNF-a) independent cultures. (B) CTGF mRNA levels in
®broblasts were analyzed by Northern blotting after treatment with
various concentrations of IL-1a for 16 h in the presence or absence of
20 pM TGF-b1. The experiment was repeated with identical results.
Figure 9. Neutralizing anti-IL-1a antibodies reverse keratinocyte-
mediated suppression of CTGF in ®broblasts. CTGF mRNA levels
in ®broblasts were analyzed by Northern blotting after treatment with
keratinocyte-conditioned medium in the absence or presence of
neutralizing anti-IL-1a antibodies. Twenty picomoles TGF-b1 was added
to the keratinocyte-conditioned medium. Values are expressed as means
6 SEM of three independent experiments (using 0.4 mg per ml antibody).
FCM, ®broblast-conditioned medium (control); KCM, keratinocyte-
conditioned medium.
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